05 October 2023
05 October 2023
The vaccine candidate will progress to a Phase III trial starting later this year after positive results from the Phase I/II trial.
The initiative was created in partnership with Medicines Discovery Catapult, the Medical Research Council, and Innovate UK.
The Australian company developing ARG-007 to treat death of brain cells following a stroke has received the nod to begin Phase II trials.
The data and defense company may win a contract to overhaul the UK health service's data collection and management.
The company announced positive results from Part I of the study in February.
Multiple safety and efficacy readings from the trial are anticipated during the next six to 18 months.
The secondary objective of the study is to assess the pharmacokinetics of SAD and MAD dose levels.
VE202 consist of 16 strains of bacteria that reverse the gut microbiota abnormalities and induce immune tolerance in the gut.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
